Dongying Liao, Jiayu Liu, Qingpeng Jin, Xiaoqun Wang, Na Wang, Yingjie Jia, Fanming Kong
{"title":"A Review of the Progress in the Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma.","authors":"Dongying Liao, Jiayu Liu, Qingpeng Jin, Xiaoqun Wang, Na Wang, Yingjie Jia, Fanming Kong","doi":"10.2174/0115680096341070250109074108","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary sarcomatoid carcinoma（PSC）is a rare pathological type of non-small cell lung cancer that combines the characteristics of epithelial and mesenchymal tu-mors and is an extremely malignant and highly heterogeneous malignant tumor. PSC is dif-ficult to diagnose and has a poor sensitivity to radiotherapy. In recent years, with the effica-cy breakthroughs of molecularly targeted drugs and immune checkpoint inhibitors in tumor therapy, the treatment of PSC is gradually exploring precise targeted therapy and immuno-therapy. In this article, we will provide a comprehensive review of the clinical features, di-agnostic points, and progress in the clinical therapeutic research of PSC. We hope to provide guidance and help with clinical treatment and scientific research.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096341070250109074108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary sarcomatoid carcinoma（PSC）is a rare pathological type of non-small cell lung cancer that combines the characteristics of epithelial and mesenchymal tu-mors and is an extremely malignant and highly heterogeneous malignant tumor. PSC is dif-ficult to diagnose and has a poor sensitivity to radiotherapy. In recent years, with the effica-cy breakthroughs of molecularly targeted drugs and immune checkpoint inhibitors in tumor therapy, the treatment of PSC is gradually exploring precise targeted therapy and immuno-therapy. In this article, we will provide a comprehensive review of the clinical features, di-agnostic points, and progress in the clinical therapeutic research of PSC. We hope to provide guidance and help with clinical treatment and scientific research.
期刊介绍：
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
